Jenny Rooke (Genoa Ventures)
April 22, 2021 07:32 AM EDTUpdated 08:12 AM
People
Financing

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

Kyle Blankenship

When Jen­ny Rooke first heard of Zymer­gen back in 2014, she knew she was look­ing at some­thing dif­fer­ent and ex­cit­ing. The Emeryville, CA biotech held …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times